

# NEXT GENERATION SEQENCING **Technologies, Applications & Analysis**

AGTCCGCGAATACAGGCTCGGTAGTCCGCGAATACAGGCTCGGT

**Petrus Tang, Ph.D. (鄧致剛)**

**Graduate Institute of Basic Medical Sciences**

**and**

**Bioinformatics Center, Chang Gung University.**


petang@mail.cgu.edu.tw

<http://petang.cgu.edu.tw>



**60**  
**DNA**  
1953 - 2013

*Nature No.4356 Apr 25,  
1953,*



James Watson and Francis Crick with their DNA model at the Cavendish Laboratories in 1953



# The Nobel Prize in Chemistry 1980

"for his fundamental studies of the biochemistry of nucleic acids, with particular regard to recombinant-DNA"

"for their contributions concerning the determination of base sequences in nucleic acids"



**Paul Berg**

Recombinant DNA

🕒 1/2 of the prize

USA

Stanford University  
Stanford, CA, USA



**Walter Gilbert**

Chemical sequencing

🕒 1/4 of the prize

USA

Harvard University,  
Biological Laboratories  
Cambridge, MA, USA



**Frederick Sanger**

Chain-termination sequencing

🕒 1/4 of the prize

United Kingdom

MRC Laboratory of  
Molecular Biology  
Cambridge, United

*Proc. Natl. Acad. Sci. USA*  
Vol. 74, No. 12, pp. 5463-5467, December 1977  
Biochemistry



## DNA sequencing with chain-terminating inhibitors

(DNA polymerase/nucleotide sequences/bacteriophage  $\phi$ X174)


F. SANGER, S. NICKLEN, AND A. R. COULSON

Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 2QH, England

Contributed by F. Sanger, October 3, 1977



# Sanger Dideoxy Sequencing



Sanger, F. et al. Nature 24, 687–695 (1977).

Sanger, F., Nicklen, S. & Coulson, A.R. Proc. Natl. Acad. Sci. USA 74, 5463–5467 (1977).




# February 2001: Completion of the Draft Human Genome >10 years to finish USD 3 billion



*Science*, 16 February 2001  
Vol. 291, Pages 1145-1434



*Nature*, 15 February 2001  
Vol. 409, Pages 813-960



## April 2003: High-Resolution Human Genome

A vision for the future of genomics research


A blueprint for the genomic era.

Francis S. Collins, Eric D. Green,  
Alan E. Guttmacher and Mark S.  
Guyer on behalf of the US National  
Human Genome Research Institute\*

**50** Years of DNA: *From Double Helix to Health*  
A Celebration of the Genome

*Nature*, 23 April 2003  
Vol. 422, Pages 1-13

# Human Genome Project




3 billion basepairs


# Human Genome Project

# 3G

3 billion basepairs



# ABI 3730 XL DNA Sequencer




96/384 DNA sequencing in 2 hrs, approximately 600-1000 readable bps per run.

1-4 MB bps/day

*A human genome of 3GB need 750 days to finish 1X coverage*



*Whitehead Institute*





The Sequence of the Human Genome

J. Craig Venter, Mark D. Adams, Eugene W. Myers, Peter W. Li, Richard J. Mural, Granger G. Sutton, Hamilton O. Smith, Mark Yandell, Cheryl A. Evans, Robert A. Hott, Jeannine D. Gocayne, Peter Amanatides, Richard M. Ballwe, Daniel H. Huson, Jennifer Russo Wortman, Qing Zhang, Chinnappa D. Kodira, Xiangqun H. Zheng, Lin Chen, Marian Skupski, Gangadharan Subramanian, Paul D. Thomas, Jinghui Zhang, George L. Gabor Miklos, Catherine Nelson, Samuel Broder, Andrew G. Clark, Joe Nadeau, Victor A. McKusick, Norton Zinder, Arnold J. Levine, Richard J. Roberts, Mel Simon, Carolyn Slayman, Michael Hunkapiller, Randall Bolanos, Arthur Delcher, Ian Dew, Daniel Fasulo, Michael Flanigan, Liliana Florea, Aaron Halpern, Sridhar Hannehalli, Saul Kravitz, Samuel Levy, Clark Mobarry, Knut Reinert, Karin Remington, Jane Abu-Threideh, Ellen Beasley, Kendra Biddick, Vivien Bonazzi, Rhonda Brandon, Michele Cargill, Ishwar Chandramouliswaran, Rosane Charlab, Kabir Chaturvedi, Zuoming Deng, Valentina Di Francesco, Patrick Dunn, Karen Eilbeck, Carlos Evangelista, Andrei E. Gabrielian, Weiniu Gan, Wangmao Ge, Fangcheng Gong, Zhiping Gu, Ping Guan, Thomas J. Heiman, Maureen E. Higgins, Rui-Ru Ji, Zhaoxi Ke, Karen A. Ketchum, Zhongwu Lai, Yiding Lei, Zhenya Li, Jiayin Li, Yong Liang, Xiaoying Lin, Fu Lu, Gennady V. Merkulov, Natalia Milshina, Helen M. Moore, Ashwinikumar K Naik, Vaibhav A. Narayan, Beena Neelam, Deborah Nusskern, Douglas B. Rusch, Steven Salzberg, Wei Shao, Bixiong Shue, Jingtao Sun, Zhen Yuan Wang, Aihui Wang, Xin Wang, Jian Wang, Ming-Hui Wei, Ron Whaley, Chunlin Xiao, Chunhua Yao, Alison Yao, Jane Ye, Ming Zhan, Weiqing Zhang, Hongyu Zhang, Qi Zhao, Liansheng Zheng, Fei Zhong, Wenyang Zhong, Shiaoping C. Zhu, Shaying Zhao, Dennis Gilbert, Suzanna Baumhueter, Gene Spier, Christine Carter, Anibal Cravchik, Trevor Woodage, Feroze Ali, Huijin An, Aderonke Awe, Danita Baldwin, Holly Baden, Mary Barnstead, Ian Barrow, Karen Beeson, Dana Busam, Amy Carver, Angela Center, Ming Lai Cheng, Liz Curry, Steve Danaher, Lionel Davenport, Raymond Desilets, Susanne Dietz, Kristina Dodson, Lisa Doup, Steven Ferreira, Neha Garg, Andras Gluecksmann, Brit Hart, Jason Haynes, Charles Haynes, Cheryl Hainer, Suzanna Hladun, Damon Hostin, Jarrett Houck, Timothy Howland, Chinyere Ibegwam, Jeffery Johnson, Francis Kalush, Lesley Kline, Shashi Koduru, Amy Love, Felecia Mann, David May, Steven McCawley, Tina McIntosh, Mee Moy, Linda Moy, Brian Murphy, Keith Nelson, Cynthia Pfannkoch, Eric Pratts, Vinita Puri, Hina Qureshi, Matthew Reardon, Robert Rodriguez, Yu-Hui Rogers, Deanna Romblad, Bob Ruhfel, Richard Scott, Cynthia Sitter, Michelle Smallwood, Erin Stewart, Renee Strong, Ellen Suh, Reginald Thomas, Ni Ni Tint, Sukyee Tse, Claire Vech, Gary Wang, Jeremy Wetter, Sherita Williams, Monica Williams, Sandra Windsor, Emily Winn-Deen, Keriellen Wolfe, Jayshree Zaveri, Karena Zaveri, Josef F. Abril, Roderic Guigo, Michael J. Campbell, Kimmen V. Sjolander, Brian Kartak, Anish Kejarival, Huaiyu Mi, Betty Lazareva, Thomas Hatton, Apurva Narechania, Karen Diemer, Anushya Muruganujan, Nan Guo, Shinji Sato, Vineet Bafna, Sorin Istrail, Ross Lippert, Russell Schwartz, Brian Walenz, Shibu Yooseph, David Allen, Anand Basu, James Baxendale, Louis Blick, Marcelo Caminha, John Carnes-Stine, Parris Caulk, Yen-Hui Chiang, My Coyne, Carl Dahlke, Anne Deslattes Mays, Maria Dombroski, Michael Donnelly, Dale Ely, Shiva Esparham, Carl Foster, Harold Gire, Stephen Glanowski, Kenneth Glasser, Anna Glodek, Mark Gorokhov, Ken Graham, Barry Gropman, Michael Harris, Jeremy Heil, Scott Henderson, Jeffrey Hoover, Donald Jennings, Catherine Jordan, John Kasha, Leonid Kagan, Cheryl Kraft, Alexander Levitsky, Mark Lewis, Xiangjun Liu, John Lopez, Daniel Ma, William Majoros, Joe McDaniel, Sean Murphy, Matthew Newman, Trung Nguyen, Ngoc Nguyen, Marc Nodell, Sue Pan, Jim Peck, Marshall Peterson, William Rowe, Robert Sanders, John Scott, Michael Simpson, Thomas Smith, Arlan Sprague, Timothy Stockwell, Russell Turner, Eli Venter, Mei Wang, Meiyuan Wen, David Wu, Mitchell Wu, Ashley Xia, Ali Zandieh, Xiaohong Zhu



Initial sequencing and analysis of the human genome

International Human Genome Sequencing Consortium\*

Genome Sequencing Centres (Listed in order of total genomic sequence contributed, with a partial list of personnel. A full list of contributors at each centre is available as Supplementary Information.)

Whitehead Institute for Biomedical Research, Center for Genome Research: Eric S. Lander, Lauren M. Linton, Bruce Birren, Chad Nusbaum, Michael C. Zody, Jennifer Baldwin, Ken Devor, Ken Dewar, Michael Doyle, William Fitzhugh, Roel Funke, Diane Gage, Katrina Harris, Andrew Heaford, John Howland, Lisa Kann, Jessica Lehoczky, Rosie Levine, Paul McEwan, Kevin McKernan, James Meldrum, Jill P. Mesirov, Cher Miranda, William Morris, Jerome Naylor, Christina Raymond, Mark Rosetti, Ralph Santos, Andrew Sheridan, Carrie Sougnez, Nicole Stange-Thomann, Nikola Stojanovic, Aravind Subramanian & Dudley Wyman

The Sanger Centre: Jane Rogers, John Sulston, Rachael Ainscough, Stephan Beck, David Bentley, John Burton, Christopher Clee, Nigel Carter, Alan Coulson, Rebecca Deadman, Pamos Deloukas, Andrew Dunham, Ian Dunham, Richard Durbin, Lisa French, Daren Grafham, Simon Gregory, Tim Hubbard, Sean Humphray, Adrienne Hunt, Matthew Jones, Christine Lloyd, Amanda McMurray, Lucy Matthews, Simon Mercer, Sarah Milne, James C. Mullikin, Andrew Mungall, Robert Plumb, Mark Ross, Ratna Showkeen & Sarah Sims

Washington University Genome Sequencing Center: Robert H. Waterston, Richard K. Wilson, LaDeana W. Hillier, John D. McPherson, Marco A. Marra, Elaine R. Mardis, Lucinda A. Fulton, Asif T. Chinwalla, Kimberlie H. Pepin, Warren R. Gish, Stephanie L. Chissoe, Michael C. Wendt, Kim D. Delehaunty, Tracie L. Miner, Andrew Delehaunty, Jason B. Kramer, Lisa L. Cook, Robert S. Fulton, Douglas L. Johnson, Patrick J. Minx & Sandra W. Clifton

US DOE Joint Genome Institute: Trevor Hawkins, Elbert Branscomb, Paul Predki, Paul Richardson, Sarah Wrenning, Tom Sleczak, Norman Doggett, Jan-Fang Cheng, Anne Olsen, Susan Lucas, Christopher Elkin, Edward Uberbacher & Marvin Frazier

Baylor College of Medicine Human Genome Sequencing Center: Richard A. Gibbs, Donna M. Muzny, Steven E. Scherer, John B. Bouck, Erica J. Sodergren, Kim C. Worley, Catherine M. Rives, James H. Gornall, Michael L. Metzker, Susan L. Naylor, Raju S. Kuchertapu, David L. Nelson, & George M. Weinstock

RIKEN Genome Sequencing Center: Yoshiyuki Sakaki, Asao Fujiyama, Masahira Hattori, Tetsushi Yada, Atsushi Toyoda, Takehiko Itoh, Chiharu Kawagoe, Hiromi Watanabe, Yasushi Totoki & Todd Taylor

Genoscope and CNRS UMR-8030: Jean Weissenbach, Roland Heilig, William Saurin, Francois Artiguenave, Philippe Brothier, Thomas Bruls, Eric Pelletier, Catherine Robert & Patrick Wincker

GTC Sequencing Center: Douglas R. Smith, Lynn Doucette-Stamm, Marc Rubinfeld, Keith Weinstock, Hong Mei Lee & JoAnn Dubois

Department of Genome Analysis, Institute of Molecular

Biotechnology: André Rosenthal, Matthias Platzer, Gerald Nyakatura, Stefan Taudien & Andreas Rump

Beijing Genomics Institute/Human Genome Center: Kuaning Yang, Jun Yu, Jian Wang, Guyang Huang & Jun Gu

Multimegabase Sequencing Center, The Institute for Systems Biology: Leroy Hood, Lee Rowen, Anup Madan & Shizen Qin

Stanford Genome Technology Center: Ronald W. Davis, Nancy A. Federspiel, A. Pia Abola & Michael J. Proctor

Stanford Human Genome Center: Richard M. Myers, Jeremy Schmutz, Mark Dickson, Jane Grimwood & David R. Cox

University of Washington Genome Center: Maynard V. Olson, Rajinder Kaul & Christopher Raymond

Department of Molecular Biology, Keio University School of Medicine: Nobuyoshi Shimizu, Kazuhiko Kawasaki & Shinsai Minoshima

University of Texas Southwestern Medical Center at Dallas: Gen A. Evans, Martha Athanasiou & Roger Schultz

University of Oklahoma's Advanced Center for Genome Technology: Bruce A. Roe, Fong Chen & Huaqin Pan

Max Planck Institute for Molecular Genetics: Juliane Ramser, Hans Lehrach & Richard Reinhardt

Cold Spring Harbor Laboratory, Lita Annenberg Hazen Genome Center: W. Richard McCombie, Melissa de la Bastide & Neilay Dedia

GBF—German Research Centre for Biotechnology: Helmut Blöcker, Klaus Homischer & Gabriele Nordick

\* Genome Analysis Group (listed in alphabetical order, also includes individuals listed under other headings): Richa Agarwala, L. Aravind, Jeffrey A. Bailey, Alex Bateman, Serafim Batzoglou, Ewan Birney, Peer Bork, Daniel G. Brown, Christopher B. Burge, Lorenzo Coruzzi, Hsiu-Chuan Chen, Deanna Church, Michele Clamp, Richard R. Copley, Tobias Doerk, Sean R. Eddy, Evan E. Eichler, Terrence S. Furey, James Galagan, James G. R. Gilbert, Cyrus Harmon, Yoshitake Hayashizaki, David Haussler, Henning Hermjakob, Karsten Hokamp, Wonhee Jung, L. Steven Johnson, Thomas A. Jones, Simon Kashef, Ark Kasparyk, Scot Kennedy, W. James Kent, Paul Kitts, Eugene V. Koonin, Ian Korf, David Kulp, Doron Lancet, Todd M. Lowe, Aoife McLysaght, Tarjei Mikkelser, John V. Moran, Nicola Mulder, Victor J. Pollara, Chris P. Ponting, Greg Schulz, Jörg Schultz, Guy Slater, Arian F. A. Smit, Elia Stupka, Joseph Szustakowski, Danielle Thierry-Mieg, Jean Thierry-Mieg, Lukas Wagner, John Wallis, Raymond Wheeler, Alan Williams, Yut I. Wolf, Kenneth H. Wolfe, Shiaw-Pyng Yang & Ru-Fang Yeh

Scientific management: National Human Genome Research Institute, US National Institutes of Health: Francis Collins, Mark S. Guyer, Jane Peterson, Adam Felsenfeld & Kris A. Wetterstrand; Office of Science, US Department of Energy: Anstoes Patrinos; The Wellcome Trust: Michael J. Morgan

RESEARCH

Open Access

# Sequencing and analysis of an Irish human genome

Pin Tong<sup>1†</sup>, James GD Prendergast<sup>2†</sup>, Amanda J Lohan<sup>1</sup>, Susan M Farrington<sup>2,3</sup>, Simon Cronin<sup>4</sup>, Nial Friel<sup>5</sup>, Dan G Bradley<sup>6</sup>, Orla Hardiman<sup>7</sup>, Alex Evans<sup>8</sup>, James F Wilson<sup>9</sup>, Brendan Loftus<sup>1\*</sup>

## Abstract

**Background:** Recent studies generating complete human sequences from Asian, African and European subgroups have revealed population-specific variation and disease susceptibility loci. Here, choosing a DNA sample from a population of interest due to its relative geographical isolation and genetic impact on further populations, we extend the above studies through the generation of 11-fold coverage of the first Irish human genome sequence.

**Results:** Using sequence data from a branch of the European ancestral tree as yet unsequenced, we identify variants that may be specific to this population. Through comparisons with HapMap and previous genetic association studies, we identified novel disease-associated variants, including a novel nonsense variant putatively associated with inflammatory bowel disease. We describe a novel method for improving SNP calling accuracy at low genome coverage using haplotype information. This analysis has implications for future re-sequencing studies and validates the imputation of Irish haplotypes using data from the current Human Genome Diversity Cell Line Panel (HGDP-CEPH). Finally, we identify gene duplication events as constituting significant targets of recent positive selection in the human lineage.

**Conclusions:** Our findings show that there remains utility in generating whole genome sequences to illustrate both general principles and reveal specific instances of human biology. With increasing access to low cost sequencing we would predict that even armed with the resources of a small research group a number of similar initiatives geared towards answering specific biological questions will emerge.



## Whole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencing

Akihiro Fujimoto, Hidewaki Nakagawa, Naoya Hosono, Kaoru Nakano, Tetsuo Abe, Keith A Boroevich, Masao Nagasaki, Rui Yamaguchi, Tetsuo Shibuya, Michiaki Kubo, Satoru Miyano, Yusuke Nakamura & Tatsuhiko Tsunoda

[Affiliations](#) | [Contributions](#) | [Corresponding authors](#)

*Nature Genetics* 42, 931–936 (2010) | doi:10.1038/ng.691

Received 18 February 2010 | Accepted 10 September 2010 | Published online 24 October 2010

### Abstract

[Abstract](#) • [Author information](#) • [Supplementary information](#)


We report the analysis of a Japanese male using high-throughput sequencing to  $\times 40$  coverage. More than 99% of the sequence reads were mapped to the reference human genome. Using a Bayesian decision method, we identified 3,132,608 single nucleotide variations (SNVs). Comparison with six previously reported genomes revealed an excess of singleton nonsense and nonsynonymous SNVs, as well as singleton SNVs in conserved non-coding regions. We also identified 5,319 deletions smaller than 10 kb with high accuracy, in addition to copy number variations and rearrangements. *De novo* assembly of the unmapped sequence reads generated around 3 Mb of novel sequence, which showed high similarity to non-reference human genomes and the human herpesvirus 4 genome. Our analysis suggests that considerable variation remains undiscovered in the human genome and that whole-genome sequencing is an invaluable tool for obtaining a complete understanding of human genetic variation.



# Next Generation Sequencing Technology

Massively Parallel Signature Sequencing (MPSS)

NATURE METHODS | VOL.5 NO.1 | JANUARY 2008



**Nature Methods' Method of the Year 2007 goes to next-generation sequencing.** This series of articles showcase how these novel sequencing methods came into their own in 2007 and the incredible impact they promise to have in a variety of research applications. The Methods to Watch feature provide a glimpse and a wish list for future Methods of the Year.



**454 GS FLX**

<http://www.454.com/>

illumina® **SOLEXA**

<http://www.illumina.com/pages.ilmn?ID=250>

**AB** applied biosystems™ **SOLID**


<http://marketing.appliedbiosystems.com/>

# Throughput of NGS machines (2007-2009)

Throughput = total number of reads x read length

Vendor:	Roche			Illumina		ABI		
Technology:	454			Solexa		SOLiD		
Platform:	GS 20	FLX	Ti	GA	GA II	1	2	
Reads:	500 k	500 k	1 M	28 M	80 M	40 M	115 M	
<b>Fragment</b>								
Read length:	100	200	350	35	50	75	25	35
Run time:	6 hr	7 hr	9 hr	3 d	3 d	4 d	6 d	5 d
Yield:	50 Mb	100 Mb	400 Mb	1 Gb	4 Gb	6 Gb	1 Gb	4 Gb
Images:	11 GB	13 GB	27 GB	500 GB	1.1 TB	1.7 TB	1.8 TB	2.5 TB
PA Disk:	3 GB	3 GB	15 GB	175 GB	300 GB	350 GB	300 GB	750 GB
PA CPU:	10 hr	140 hr	220 hr	100 hr	70 hr	100 hr	NA	NA
SRA:	500 MB	1 GB	4 GB	30 GB	50 GB	75 GB	100 GB	140 GB
<b>Paired-end</b>								
Read length:		200		2x35	2x50	2x75	2x25	2x35
Insert:		3.5 kb		200 b	200 b	200 b	3 kb	3 kb
Run time:		7 hr		6 d	6 d	8 d	12 d	10 d
Yield:		100 Mb		2 Gb	8 Gb	11 Gb	2 Gb	8 Gb
Images:		13 GB		1 TB	2.2 TB	3.4 TB	3.6 TB	5 TB
PA Disk:		3 GB		350 GB	500 GB	600 GB	600 GB	1.5 TB
PA CPU:		140 hr		160 hr	120 hr	170 hr	NA	NA
SRA:		1 GB		60 GB	100 GB	150 GB	200 GB	280 GB

# Throughput of NGS machines (2012-2013)



# Throughput of NGS machines (2012)



GS FLX+ System Performance	
Read Length	Up to 1,000 bp
Mode Read Length	700 bp
Throughput Profile	85% of total bases from reads >500 bp 45% of total bases from reads >700 bp
Typical Throughput	700 Mb
Reads per Run	1,000,000
Consensus Accuracy*	99.997%
Run Time	23 hours



GS Junior System	
Read Length	~400 bp
Throughput Profile	- 85% of total bases from reads >400 bp in length - 45% of total bases from reads >500 bp in length*
Throughput	~35 Mb



# Throughput of NGS machines (2012)



## HiSeq 2500/1500

**Two run modes. High output or rapid run.**

*Flexibility to batch process multiple samples with high output in a single run, or get rapid results with fewer samples for time-critical studies.*

	HiSeq 2500		HiSeq 1500	
Run Mode	High Output	Rapid Run*	High Output	Rapid Run*
Output (2 × 100 bp)	600 Gb	120 Gb	300 Gb	60 Gb
Run Time (2 × 100 bp)	~11 days	~27 hours	~8.5 days	~27 hours
Cluster Generation	cBot	On board	cBot	On board
Paired-end Reads	6 Billion	1.2 Billion	3 Billion	600 Million
Single Reads	3 Billion	600 Million	1.5 Billion	300 Million
Maximum Read Length**	2 × 100 bp	2 × 150 bp	2 × 100 bp	2 × 150 bp
Quality Scores***	> 85% (2 × 50 bp) > 80% (2 × 100 bp)			

## HiSeq 2000/1000

**One run mode. High output.**

*Generate the highest output and number of reads for batch processing multiple samples in a single run.*

	HiSeq 2000	HiSeq 1000
Output (2 × 100 bp)	600 Gb	300 Gb
Run Time (2 × 100 bp)	~11 days	~8.5 days
Cluster Generation	cBot	cBot
Paired-end Reads	6 Billion	3 Billion
Single Reads	3 Billion	1.5 Billion
Maximum Read Length**	2 × 100 bp	2 × 100 bp
Quality Scores***	> 85% (2 × 50 bp) > 80% (2 × 100 bp)	

# Throughput of NGS machines (2012)



	5500 SOLiD™ Sequencer with microbeads	5500xl SOLiD™ Sequencer with microbeads	5500xl SOLiD™ Sequencer with nanobeads
<b>System accuracy<sup>1</sup></b>	up to 99.99%	up to 99.99%	up to 99.99%
<b>Typical throughput/day<sup>2</sup></b>	10–15 Gb/day	20–30 Gb/day	30–45 Gb/day
<b>Samples/run<sup>3</sup></b>	<ul style="list-style-type: none"> <li>• 1 genome</li> <li>• 12 exomes</li> <li>• 6 transcriptomes</li> </ul>	<ul style="list-style-type: none"> <li>• 2 genomes</li> <li>• 24 exomes</li> <li>• 12 transcriptomes</li> </ul>	<ul style="list-style-type: none"> <li>• 3 genomes</li> <li>• 40 exomes</li> <li>• 20 transcriptomes</li> </ul>
<b>Independent lanes</b>	1–6	1–12	1–12
<b>Typical run time</b>	<ul style="list-style-type: none"> <li>• 1 day for 35 bp (1 lane)</li> <li>• 7 days for 60 bp x 60 bp (6 lanes)</li> <li>• 7 days for 75 bp x 35 bp (6 lanes)</li> </ul>	<ul style="list-style-type: none"> <li>• 1 day for 35 bp (1 lane)</li> <li>• 7 days for 60 bp x 60 bp (12 lanes)</li> <li>• 7 days for 75 bp x 35 bp (12 lanes)</li> </ul>	<ul style="list-style-type: none"> <li>• 1 day for 35 bp (1 lane)</li> <li>• 7 days for 60 bp x 60 bp (12 lanes)</li> <li>• 7 days for 75 bp x 35 bp (12 lanes)</li> </ul>
<b>Typical throughput/run<sup>4</sup></b>	90 Gb	180 Gb	300 Gb
<b>Read length</b>	<ul style="list-style-type: none"> <li>• MP: 60 bp x 60 bp</li> <li>• PE: 75 bp x 35 bp</li> <li>• Fragment: 75 bp</li> </ul>	<ul style="list-style-type: none"> <li>• MP: 60 bp x 60 bp</li> <li>• PE: 75 bp x 35 bp</li> <li>• Fragment: 75 bp</li> </ul>	<ul style="list-style-type: none"> <li>• MP: 60 bp x 60 bp</li> <li>• PE: 75 bp x 35 bp</li> <li>• Fragment: 75 bp</li> </ul>
<b>Multiplexing</b>	96 for RNA and DNA	96 for RNA and DNA	96 for RNA and DNA

# NEXT GENERATION SEQENCING

## Basis Principles

# NGS

	Feature generation	Sequencing by synthesis
454	Emulsion PCR	Polymerase (pyrosequencing)
Solexa	Bridge PCR	Polymerase (reversible terminators)
SOLiD	Emulsion PCR	Ligase (octamers with two-base encoding)






# 454 SEQUENCING


<b>June 2000</b>	454 Life Sciences is founded
<b>October 2005</b>	Release of the Genome Sequencer 20, the first next-generation sequencing system on the market
<b>October 2005</b>	Collaboration agreement signed with Roche Diagnostics
<b>December 2005</b>	454 Life Sciences Awarded the Wall Street Journal's Gold Medal for Innovation
<b>November 2006</b>	454 Life Sciences, in collaboration with Svante Paabo, describes in <i>Nature</i> the first million base pairs of the Neanderthal genome and initiates the Neanderthal Genome Project.
<b>January 2007</b>	Release of the Genome Sequencer FLX System
<b>March 2007</b>	Roche Diagnostics completes integration with 454 Life Sciences
<b>May 2007</b>	Complete sequence of Jim Watson published in <i>Nature</i> . First genome to be sequenced for less than \$1 million.
<b>November 2007</b>	Announcement of the 100th peer-reviewed publication enabled by 454 Sequencing
<b>June 2008</b>	454 Joins the 1000 Genome Project, an international effort to build the most detailed map to date of human genetic variation as a tool for medical research
<b>September 2008</b>	Announcement of the 250th peer-reviewed publication enabled by 454 Sequencing
<b>October 2008</b>	Release of Genome Sequencer FLX Titanium Series reagents, featuring 1 million reads at 400 base pairs in length












# Step 1. DNA Library Preparation




## Step 2. Emulsion PCR (emPCR)




# Step 3. Pyrosequencing




result → read the signal of light



DNA polymerase → add the A.T.C.G




ATP sulfurylase → convert pyrophosphate to ATP



luciferase → react the ATP with luciferin to generate light

apyrase → degrade unincorporated dNTPs and excess ATP






# 454 technology (Pyrosequencing)

## Sample preparation.

Fragments of DNA are ligated to adapters that facilitate their capture on beads (one fragment per bead). A water-in-oil emulsion containing PCR reagents and one bead per droplet is created to amplify each fragment individually in its droplet. After amplification, the emulsion is broken, DNA is denatured and the beads, containing one amplified DNA fragment each, are distributed into the wells of a fiber-optic slide.

## Pyrosequencing.


The wells are loaded with sequencing enzymes and primer (complementary to the adapter on the fragment ends), then exposed to a flow of one unlabeled nucleotide at a time, allowing synthesis of the complementary strand of DNA to proceed. When a nucleotide is incorporated, pyrophosphate is released and converted to ATP, which fuels the luciferase-driven conversion of luciferin to oxyluciferin and light. As a result, the well lights up. The read length is between 100 and 150 nucleotides.



First look

Raising the standards in sequencing.  
What's coming next from 454.

See the Future of 454 Sequencing



## Roche Shutting Down 454 Sequencing Business

October 15, 2013

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche is shuttering its 454 Life Sciences sequencing operations and laying off about 100 employees, the company confirmed today.

The 454 sequencers will be phased out in mid-2016, and the 454 facility in Branford, Conn., will be closed "accordingly," Roche said in a statement e-mailed to *GenomeWeb Daily News*.

aA Type size:

Email

Printer-friendly version

RSS Feed


# Solexa HiSeq






# Solexa Genome Analyzer

1. PREPARE GENOMIC DNA SAMPLE




Randomly fragment genomic DNA and ligate adapters to both ends of the fragments.

2. ATTACH DNA TO SURFACE




Bind single-stranded fragments randomly to the inside surface of the flow cell channels.

3. BRIDGE AMPLIFICATION




Add unlabeled nucleotides and enzyme to initiate solid-phase bridge amplification.

4. FRAGMENTS BECOME DOUBLE STRANDED




The enzyme incorporates nucleotides to build double-stranded bridges on the solid-phase substrate.

5. DENATURE THE DOUBLE-STRANDED MOLECULES




Denaturation leaves single-stranded templates anchored to the substrate.

6. COMPLETE AMPLIFICATION



Several million dense clusters of double-stranded DNA are generated in each channel of the flow cell.

7. DETERMINE FIRST BASE




First chemistry cycle: to initiate the first sequencing cycle, add all four labeled reversible terminators, primers and DNA polymerase enzyme to the flow cell.

8. IMAGE FIRST BASE




After laser excitation, capture the image of emitted fluorescence from each cluster on the flow cell. Record the identity of the first base for each cluster.

9. DETERMINE SECOND BASE




Second chemistry cycle: to initiate the next sequencing cycle, add all four labeled reversible terminators and enzyme to the flow cell.

10. IMAGE SECOND CHEMISTRY CYCLE




After laser excitation, collect the image data as before. Record the identity of the second base for each cluster.

11. SEQUENCE READS OVER MULTIPLE CHEMISTRY CYCLES



Repeat cycles of sequencing to determine the sequence of bases in a given fragment a single base at a time.

12. ALIGN DATA




Align data, compare to a reference, and identify sequence differences.


# Cluster Generation



Clusters Array




Template Bridging







## Denaturation




## Ready For Sequencing




# Sequencing-By-Synthesis








**Sequence Generated At Every Site On The Array**



**a Illumina/Solexa — Reversible terminators**



## Base calling from raw data



The identity of each base of a cluster is read off from sequential images






# Solexa technology (sequencing-by-synthesis)

## Sample preparation.

Fragments of DNA are ligated to end adapters, denatured and bound at one end to a solid surface already coated with a dense layer of the adapters. Each single stranded fragment is immobilized at one end, while its free end 'bends over' and hybridizes to a complementary adapter on the surface, which initiates the synthesis of the complementary strand in the presence of amplification reagents. Multiple cycles of this solid-phase amplification followed by denaturation create clusters of ~1,000 copies of single-stranded DNA molecules distributed randomly on the surface.

## Sequencing with reversible terminators.


Synthesis reagents, added to the flow cell, consist of primers, DNA polymerase and four differently labeled, reversible terminator nucleotides. After incorporation of a nucleotide, which is identified by its color, the 3' terminator on the base and the fluorophore are removed, and the cycle is repeated for a read length of 30–35 nucleotides.



applied  
**biosystems**<sup>®</sup>  
 by *life* technologies™



SOLiD M5500XL




All calculations assume optimal running efficiencies and the following coverage:


1. ~100X coverage of human exome
2. ≥100 M tags (reads) per sample
3. 2–5 M tags (reads) per sample
4. 2–5 M tags (reads) per sample
5. 4–5X coverage of human genome
6. 60 M tags (reads) per sample

*life*  
 technologies™

# Step 1. Library preparation




# Step 2. Emulsion PCR




# Step 3. Sequencing-by-Ligation


## 1. Prime and Ligate



## 2. Image



## 3. Cap Unextended Strands





#### 4. Cleave off Fluor




#### 5. Repeat steps 1-4 to Extend Sequence


Ligation cycle 1 2 3 4 5 6 7 ... (n cycles)




#### 6. Primer Reset



## 7. Repeat steps 1-5 with new primer



## 8. Repeat Reset with , n-2, n-3, n-4 primers



Its format is

>TAG\_ID

Color\_space

>1\_88\_1830\_R3

G32113123201300232320

>1\_89\_1562\_R3

G23133131233333101320


# AB SOLiD: Dibase Sequencing

AB SOLiD reads look like this:

**T012233102**  
**TGAGCGTTC**

**T012033102**  
**TGAATAGGA**

	A	C	G	T
A	0	1	2	3
C	1	0	3	2
G	2	3	0	1
T	3	2	1	0




# SOLiD technology (sequencing-by-ligation)

## Sample preparation.

Fragments of DNA are ligated to adapters and amplified on beads by emulsion PCR. The DNA is denatured and the beads deposited onto a glass slide.

## Sequencing by ligation.

A sequencing primer is hybridized to the adapter and its 5' end is available for ligation to an oligonucleotide hybridizing to the adjacent sequence. A mixture of octamer oligonucleotides compete for ligation to the primer (the bases in fourth and fifth position on these oligos are encoded by one of four color labels). After its color has been recorded, the ligated oligonucleotide is cleaved between position 5 and 6, which removes the label, and the cycle of ligation-cleavage is repeated. In the first round, the process determines possible identities of bases in positions 4, 5, 9, 10, 14, 15, etc. The entire process is repeated, offset by one base by using a shorter sequencing primer, to determine positions 3, 4, 8, 9, 13, 14, etc., until the first base in the sequencing primer (position 0) is reached. Since the identity of this base is known, the color is used to decode its neighboring base at position 1, which in turn decodes the base at position 2, etc., until all sequence pairs are identified. The current read length is between 30 and 35 nucleotides



# Personal Sequencer

illumina®



©2011, Illumina Inc. All rights reserved.

**MiSeq**  
Personal Sequencing System

ion torrent  
by *life* technologies™



**Ion Torrent**  
Personal Genome Machine

# illumina<sup>®</sup> MiSeq Benchtop Sequencer




## MISEQ REAGENT KIT V2

READ LENGTH	TOTAL TIME*	OUTPUT
1 × 36 bp	~4 hrs	540-610 Mb
2 × 25 bp	~5.5 hrs	750-850 Mb
2 × 150 bp	~24 hrs	4.5-5.1 Gb
2 × 250 bp	~39 hrs	7.5-8.5 Gb

## MISEQ REAGENT KIT V3

READ LENGTH	TOTAL TIME*	OUTPUT
2 × 75 bp	~24 hrs	3.3-3.8 Gb
2 × 300 bp	~65 hrs	13.2-15 Gb





## 10 Mb to 1 Gb

100-fold scaling means you can choose the amount of sequencing throughput required for your specific application.




### ION PGM™ SEQUENCER

- SMALL GENOMES
- SETS OF GENES
- GENE EXPRESSION
- ChIP-SEQ



Chip Type	314	316	318
Wells (in millions)	1.2	6.2	11.1
Bases (in Mb)	>10	>100	>1000



# 90-minute run times

Rapid 100-base sequencing on the Ion 314™ Chip.

## 35–400\* bp reads

If your application requires short-read or long-read sequencing, or single-end, paired-end, or mate-paired sequencing, the Ion PGM™ Sequencer delivers the greatest flexibility.

# ion torrent



by *life* technologies™



**ion torrent**  
◊ \* △ ○ × □ + ≈


by *life* technologies™





**ion torrent**  
◊ \* △ ○ × □ + ≈

by *life* technologies™

# Ion Torrent



314 chip  
316 chip







### 10 Mb to 1 Gb


100-fold scaling means you can choose the amount of sequencing throughput required for your specific application.

#### ION PGM™ SEQUENCER

- SMALL GENOMES
- SETS OF GENES
- GENE EXPRESSION
- ChIP-SEQ



Chip Type	314	316	318
Wells (in millions)	1.2	6.2	11.1
Bases (in Mb)	>10	>100	>1000



## 90-minute run times

Rapid 100-base sequencing on the Ion 314™ Chip.

### 35–400\* bp reads

If your application requires short-read or long-read sequencing, or single-end, paired-end, or mate-paired sequencing, the Ion PGM™ Sequencer delivers the greatest flexibility.

# ROUND 1



**Table 1** Insertion/deletion and substitution errors on read level for benchtop NGS platforms

Platform	Sequencing kit	Library	Strain	Date of sequencing	Indels per 100 bp	Indels per read	Substitutions per 100 bp	Substitutions per read
GSJ	GSJ Titanium	Nebulization / AMPure XP	Sakai	June 2012	0.4011	1.8351	0.0543	0.2484
MiSeq	2 × 150-bp PE	Nextera	Sakai	June 2012	0.0009	0.0013	0.0921	0.1318
MiSeq	2 × 250-bp PE	Nextera	Sakai	September 2012	0.0009	0.0018	0.0940	0.2033
PGM	100 bp	Bioruptor / Ion Fragment Library	Sakai	July 2011	0.3520	0.3878	0.0929	0.1024
PGM	200 bp	Ion Xpress Plus Fragment	Sakai	July 2012	0.3955	0.6811	0.0303	0.0521
PGM	300 bp	Ion Xpress Plus Fragment	Sakai	August 2012	0.7054	1.4457	0.0861	0.1765
PGM	400 bp <sup>a</sup>	Ion Xpress Plus Fragment	Sakai	November 2012	0.6722	1.8726	0.0790	0.2202

Error rates were calculated by counting indels and substitutions in the mapping against the EHEC Sakai reference sequence for each uniquely mapped read.

<sup>a</sup>Kit was not officially available during time of study.

# ROUND 2

Ion Proton™ Sequencer

## The Only Benchtop Genome Center

### Human exome sequencing

Using the next generation of semiconductor technology, the Ion Proton™ I Chip will deliver whole-exome sequencing in just a few hours.



#### ION PROTON™ SEQUENCER

HUMAN GENOMES  
HUMAN EXOMES  
WHOLE TRANSCRIPTOMES

### Human genome sequencing

The Ion Proton™ II Chip will enable fast, affordable, whole-genome sequencing on your benchtop.

### 2-hour run times

Rapid 100-base sequencing runs on the Ion Proton™ I Chip.

"Cost, speed, and accuracy are key elements in the use of DNA sequencing. The technological advances in the new Ion Proton™ instrument promise to be game-changing for both research and clinical applications."

DR. RICHARD LIFTON  
YALE SCHOOL OF MEDICINE, USA



#### Ion Proton™ System performance specifications\* with Ion Proton™ I Chip at commercial launch

##### Throughput

Up to 10 Gb

(Note: The Ion Proton™ II Chip will be available about six months after the Ion Proton™ I Chip. The Ion Proton™ II Chip will enable sample-to-variant analysis of a human genome in a single day, at up to 20x coverage.)

##### Read length

Up to 200-base fragment reads

##### Sequencing run time

As little as 2 hours for 100-base reads



# Evolution of Sequencing Technology



## Sanger dideoxy-sequencing

ABI 3730XL

## Massive parallel sequencing

Roche 454-FLX, Illumina Genome Analyzer, Life Technologies SOLiD

## Bead-based em-PCR and sequencing by ligation

Dover Systems' Polonator

## Massive parallel sequencing and single molecule sequencing

**Pacific Biosciences (single-molecule real-time DNA sequencing (SMRT) technology)**

~~Helicos (true single-molecule sequencing (tSMS) technology)~~

~~VisiGen-Biotechnologies (real-time, single-molecule sequencing-fluorescence resonance energy transfer (FRET) technology)~~

## Single molecule sequencing and nanopore technology?

**Oxford Nanopore Technologies, Qiagen, Electron Optica, Electronic BioSciences, GenapSys, Genia, GnuBIO, IBM, LaserGen, Lightspeed Genomics, NABsys, NobleGen Biosciences, QuantuMDx, Reveo, Stratos Genomics, Two Pore Guys, ZS Genetics.....**

# Third-Generation Sequencers

NEW GENERATION SEQUENCING

**NGS**


# Single Molecule Real-Time Sequencing

## Real-time monitoring of PCR activity

Read-out by fluorescence resonance energy transfer between polymerase and nucleotides or


Waveguides allow direct observation of polymerase and fluorescently labeled nucleotides

c Helicos BioSciences: one-pass sequencing  
Single molecule: primer immobilized




Billions of primed, single-molecule templates

d Helicos BioSciences: two-pass sequencing  
Single molecule: template immobilized



Billions of primed, single-molecule templates

e Pacific Biosciences, Life/Visigen, LI-COR Biosciences  
Single molecule: polymerase immobilized



Thousands of primed, single-molecule templates

VisGen Biotechnologies

Pacific Biosciences

Helicos Biosciences



Helicos Sells Certain MDx IP to Sequenom for \$1.3M,  
Warns of Potential Bankruptcy

April 11, 2012

Helicos BioSciences said in a regulatory filing that it has sold certain patent applications covering molecular diagnostic applications of its technology to Sequenom for \$1.3 million. The patent applications cover methods for detecting fetal nucleic acids and diagnosing fetal abnormalities. Helicos also warned that if it is "unable to successfully raise additional capital, we may have to cease operations and/or seek bankruptcy protection."


# Single Molecule Real-Time (SMRT) Sequencing

www.sciencemag.org SCIENCE VOL 323 2 JANUARY 2009


133

## Real-Time DNA Sequencing from Single Polymerase Molecules

John Eid,\* Adrian Fehr,\* Jeremy Gray,\* Khai Luong,\* John Lyle,\* Geoff Otto,\* Paul Peluso,\* David Rank,\* Primo Baybayan, Brad Bettman, Arkadiusz Bibillo, Keith Bjornson, Bidhan Chaudhuri, Frederick Christians, Ronald Cicero, Sonya Clark, Ravindra Dalal, Alex deWinter, John Dixon, Mathieu Foquet, Alfred Gaertner, Paul Hardenbol, Cheryl Heiner, Kevin Hester, David Holden, Gregory Kearns, Xiangxu Kong, Ronald Kuse, Yves Lacroix, Steven Lin, Paul Lundquist, Congcong Ma, Patrick Marks, Mark Maxham, Devon Murphy, Insil Park, Thang Pham, Michael Phillips, Joy Roy, Robert Sebra, Gene Shen, Jon Sorenson, Austin Tomaney, Kevin Travers, Mark Trulson, John Veceli, Jeffrey Wegener, Dawn Wu, Alicia Yang, Denis Zaccarin, Peter Zhao, Frank Zhong, Jonas Korlach,† Stephen Turner†



Pacific Biosciences — Real-time sequencing






**Figure 10. Processive Synthesis with Phospholinked Nucleotides.**

Step 1: Fluorescent phospholinked labeled nucleotides are introduced into the ZMW.

Step 2: The base being incorporated is held in the detection volume for tens of milliseconds, producing a bright flash of light.

Step 3: The phosphate chain is cleaved, releasing the attached dye molecule.

Step 4-5: The process repeats.






# Nanopore Sequencing



Nucleic acids driven through a nanopore.

Differences in conductance of pore provide readout.



This diagram shows a protein nanopore set in an electrically resistant membrane bilayer. An ionic current is passed through the nanopore by setting a voltage across this membrane.

If an analyte passes through the pore or near its aperture, this event creates a characteristic disruption in current. By measuring that current it is possible to identify the molecule in question. For example, this system can be used to distinguish the four standard DNA bases and G, A, T and C, and also modified bases. It can be used to identify target proteins, small molecules, or to gain rich molecular information for example to distinguish the enantiomers of ibuprofen or molecular binding dynamics.




## Oxford Strikes First in DNA Sequencing Nanopore Wars

By Kevin Davies

**February 17, 2012** | Breaking a near total vow of silence after three years in stealth mode, Oxford Nanopore has offered stunning details of its nanopore next-generation sequencing (NGS) technology to a packed house at the premier genome sequencing conference in Marco Island, Florida.

In a talk at the Advances in Genome Biology and Technology conference this morning, [chief technology officer Clive Brown](#) presented details of what the British company calls its "new generation" of single-strand sequencing technology, featuring accurate long reads of single-stranded DNA molecules, including the completion of two viral genomes.

In the second half of this year, the company will commercially release its previously announced GridION instrument, or node, as well as the world's smallest DNA sequencing instrument – a portable cartridge called the MinION that doubles (and works as) a USB drive.



*Oxford Nanopore's disruptive MinION USB device*

## Single use cartridge

GridION nodes are designed to work with a single-use, self-contained cartridge that includes all the reagents required to run an experiment. The Company is developing a single port and a 96-well plate version of this cartridge.

All reagents are contained within the cartridge, and there are no reagents inside the instrument ([nodes](#)). The sample to be analysed is introduced into the cartridge and the cartridge inserted into the node. Cartridges are self-priming and no further user action is required once loaded.

A number of nanopores are recorded at any one time by using an arrayed [sensor chip](#) to create multiple individual recording channels. Signals from these channels are acquired by a specially-designed [ASIC](#).


### Adapting to automation and improved workflows

Multiple samples can be loaded into a cartridge via a multi-well plate manifold. This adaptation allows the node to analyse each sample in series.

Coupled with the “[Run until...](#)” functionality, each sample can be analysed until sufficient data has been gathered to satisfy the pre-determined experimental endpoint, and the node can then expel the sample, flush and move to the subsequent sample. 96-well plate-based sample preparation can streamline and scale workflows for individual nodes or for clusters.

### Adaptation of cartridges for different applications.

Cartridges may contain different types of nanopores for the analysis of different types of analyte, e.g. DNA, proteins or small molecules. A different type of nanopore may be supplied for sub-types of these experiments, for example epigenetic analyses.



## The GridION system

Oxford Nanopore's proprietary nanopore-based sensing chemistries are operated on an electronics-based platform, the GridION system. This enables the scaled-up measurements of multiple nanopores and the sensing, processing and analysis of data in real time.

A single instrument, a [GridION node](#), operates with a single-use [cartridge](#) that contains the necessary reagents to perform an experiment.

### Scalability

A node can be employed as a single desktop instrument, or scaled up in a similar way to computing installations.

As a desktop instrument for the individual researcher, it can write data to the network or a locally attached disc (directly through a USB or through a network) and work in a small lab.

Each node is a network device and multiple nodes can be aggregated together into larger co-operating units or clusters, communicating with each other in a peer-to-peer fashion over the user's network. The system is designed to interface, or even co-locate, with standard or high-performance IT infrastructure. Workflow overheads, and total costs, including IT, scale linearly with the GridION system.



*graphic: a single node (left) may be used as a desktop device, or installed in conjunction with other nodes that communicate with each other through a network (centre, right).*

*A single node as a desktop installation*



*Nodes may be clustered through a network for larger throughput installations*



*Each GridION node operates with a single disposable cartridge.*





# GeneReader



Early-access customers in 2013,  
Commercial launch in early 2014.

20 flowcells configuration

20-400M reads per flow cell

12 minutes per base sequencing-by-synthesis  
(50-bases ~10 hours)





# *Droplet-based Sequencing*

Microfluidics, the science that deals with the behavior, precise control and manipulation of fluids that are geometrically constrained to a small, typically sub-millimeter scale, emerged in the beginning of the 1980s and is used widely in technologies such as inkjet print heads, DNA chips, lab-on-a-chip technology, micro-propulsion and micro-thermal technologies. GnuBIO has adapted technology developed in Dr. David Weitz laboratory at Harvard. This technology is combined with proprietary molecular biology assays to create a unique next-generation DNA sequencing technology. The science behind this GnuBIO sequencing technology utilizes droplet microfluidics to perform the biochemical reactions for sequencing inside of tiny picoliter -sized aqueous drops. Each droplet acts as a discrete reaction vessel, like a miniature test tube, where the sequencing assay is performed.

The following results are the raw and unfiltered data from the GnuBIO prototype system:

99.993% per base accuracy: This is the true per base accuracy, and is not based on consensus accuracy

100% sequence coverage

100% of the reads were used

Read lengths of 126 base pairs (read lengths of 1Kb can routinely be achieved today)





[NEED SEQUENCING](#)

[NGS CONFERENCES](#)

[KNOWLEDGE BANK](#)

[ABOUT US](#)

[BLOG](#)

[SIGN IN](#)

[Home](#) ▶ [Knowledge Bank](#)

# The AllSeq Knowledge Bank

The Knowledge Bank is managed by employees at AllSeq. AllSeq matches people's sequencing service needs with labs that have extra capacity on their NGS instruments. [See how it works](#). This totally independent position in the sequencing market has led to great knowledge about the topic.

-The AllSeq-team

## Knowledge Bank

[Sequencing Platforms](#)

[Emerging Technologies](#)

[Electron Optica](#)

[Electronic BioSciences](#)

[GenapSys](#)

[Genia](#)

[GnuBIO](#)

[IBM](#)

[LaserGen](#)

[Lightspeed Genomics](#)

[NABsys](#)

[NobleGen Biosciences](#)

[Oxford Nanopore Technologies](#)

[Qiagen](#)

[xQuantuMDx](#)

[Reveo](#)


[Stratos Genomics](#)

[Two Pore Guys](#)

[ZS Genetics](#)



# Applications on Biomedical Sciences



**DNA** Exome Sequencing  
Genome Resequencing  
De novo Genome Sequencing  
Meta-Genomic Sequencing  
Chip-Sequencing

**RNA** Small RNA Sequencing  
Transcriptome Sequencing  
De novo Transcriptome Sequencing  
Meta-Transcriptome Sequencing

**BIOINFORMATICS**



IBM X3850